Crypto Rover Sets Targets for XRP Price for the Next 6-12 Months
XRP trades at $1.40 today. Crypto Rover’s target range for the asset sits at $3.20 to $4.80. That puts the lower end of his target at 128% above the current price. The upper target sits 243% higher.
The token dipped to $1.32 last week before recovering slightly from a recent high of $1.50. The recovery has been modest, but the asset is back near its previous level, and Crypto Rover expects a new all-time high.
Where the Major Assets Stand
Bitcoin currently trades at approximately $83,800. Rover’s target for BTC runs from $120,000 to $145,000. That represents 43% to 73% from today’s price. Ethereum trades at roughly $2,550, against a target range of $6,000 to $8,000. ETH would need to gain 135% to 213% to reach those levels.
Solana trades near $112 today. Rover’s SOL target of $400 to $700 implies a potential gain of 257% to 525%. BNB sits at approximately $754, with a target range of $950 to $1,500, requiring a 26% to 99% move.
More Targets Across the Market
Beyond the major assets, Rover’s list covers many other tokens. Chainlink (LINK) has a $280 to $450 target. Zcash (ZEC) has a target of $2,000 to $4,000. Quant (QNT) carries a target of $550 to $900.
Several smaller assets appear on the list with targets that would require substantial appreciation. Ondo (ONDO) carries a $1.50 to $3.00 target. Bittensor (TAO) has a $900 to $1,500 target. Kaspa (KAS) sits in the $0.15 to $0.25 range.
The Rationale Behind Buying Dips
Rover said he is buying these bull market dips because the listed prices are his targets for the next 6-12 months. The framing treats current price weakness as an entry opportunity rather than a warning sign.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review
Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).
4 Big Bank Earnings to Watch This Week as Wall Street Turns Bullish
Mortgage rates return to 7%, pending home sales in the US fall to nearly a twelve-year low
According to Freddie Mac data, the 30-year fixed mortgage rate has risen to 7.4%, the highest level in nearly three years. Data from real estate brokerage Redfin shows that the volume of existing home pending sales in September fell 4% month-on-month, marking the largest single-month drop in over three years and hitting the lowest level since 2014. Nearly one-fifth of sellers have reduced prices, and the home purchase contract cancellation rate has reached a record high of 14.5%. Inventory levels have risen to the highest since March 2020, but high financing costs continue to constrain transactions.

Mueller Water Products names Michael Morgan CFO, succeeding Melissa Rasmussen
